News coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has been trending positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.320606459843 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded up $1.00 on Friday, reaching $15.55. 161,364 shares of the company’s stock traded hands, compared to its average volume of 117,080. The stock has a market capitalization of $339.21, a P/E ratio of -7.27 and a beta of -14.95. Aquinox Pharmaceuticals has a 12 month low of $10.02 and a 12 month high of $17.42.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Monday, March 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). sell-side analysts anticipate that Aquinox Pharmaceuticals will post -2.27 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/2018/03/24/aquinox-pharmaceuticals-aqxp-given-daily-news-impact-rating-of-0-28/1986401.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.